FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joseph Blaney

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Physiology

Virus Replication

Anatomy

Vero Cells

Co-author Network

Publications

TOP 3
Haifeng Song; Joseph E Blaney; Russ Byrum; Marisa St Claire; Julie Dyall; Krisztina Janosko; Gerald Jennings; Catherine Jett; Reed F Johnson; Nicole Josleyn; Jing Qin; Peter B Jahrling
Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates.
Amy Papaneri; Matthias J Schnell; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Joseph E Blaney
A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.
Amy Papaneri; Matthias J Schnell; Christoph Wirblich; Kurt Cooper; Peter B Jahrling; Joseph E Blaney
Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joseph Blaney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Haifeng Song; Joseph E Blaney; Russ Byrum; Marisa St Claire; Julie Dyall; Krisztina Janosko; Gerald Jennings; Catherine Jett; Reed F Johnson; Nicole Josleyn; Jing Qin; Peter B Jahrling
Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates.
PloS one 2013;8(4):e60533.
2012: Amy Papaneri; Matthias J Schnell; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Joseph E Blaney
A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.
Virology 2012;434(1):18-26.
2012: Amy Papaneri; Matthias J Schnell; Christoph Wirblich; Kurt Cooper; Peter B Jahrling; Joseph E Blaney
Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.
Vaccine 2012;30(43):6136-41.
2012: Jason Kindrachuk; Kristen N Kindrachuk; Anthony Kusalik; Scott Napper; Brett Trost; Ryan Arsenault; Peter B Jahrling; Joseph E Blaney
Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus.
Molecular & cellular proteomics : MCP 2012;11(6):M111.015701.
2012: Sharon E Altmann; Lori E Dodd; Julie Dyall; Peter B Jahrling; Reed F Johnson; Jason Paragas; Alvin L Smith; Joseph E Blaney
Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.
Antiviral research 2012;93(2):305-8.
2012: Sharon E Altmann; Curtis R Brandt; Peter B Jahrling; Joseph E Blaney
Antiviral activity of the EB peptide against zoonotic poxviruses.
Virology journal 2012;9():6.
2011: Reed F Johnson; Jason Paragas; Dan R Ragland; Marisa St Claire; Srikanth Yellayi; John G Bernbaum; Joseph E Blaney; Russ Byrum; Jennifer A Cann; Lori E Dodd; Wenjuan Gu; Catherine Jett; Peter B Jahrling
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease.
Virology 2011;421(2):129-40.
2011: Julie Dyall; Louis Huzella; Peter B Jahrling; Gerald Jennings; Reed F Johnson; Daniel J Mollura; Joseph E Blaney; Russ Byrum; Dar-Yeong Chen; Dan R Ragland; Richard C Reba; Jason Paragas
Evaluation of monkeypox disease progression by molecular imaging.
The Journal of infectious diseases 2011;204(12):1902-11.
2011: Joseph E Blaney; Alexander Freiberg; Michael R Holbrook; Peter B Jahrling; Reed F Johnson; Terry L Juelich; Carey J Myers; Amy Papaneri; Jason Paragas; John G Bernbaum; Christoph Wirblich; Matthias J Schnell
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.
Journal of virology 2011;85(20):10605-16.
2011: Reed F Johnson; Jason Paragas; Alvin L Smith; Srikanth Yellayi; Jennifer A Cann; Peter B Jahrling; Anthony Johnson; Joseph E Blaney
Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.
Virology 2011;418(2):102-12.
2011: Anna P Durbin; Dan Elwood; Brian R Murphy; Donna Shaffer; Bhagvanji Thumar; Kimberli Wanionek; Stephen S Whitehead; Joseph E Blaney; Alexander C Schmidt
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
PLoS neglected tropical diseases 2011;5(8):e1267.
2011: Reed F Johnson; Julie Dyall; Dan R Ragland; Louis Huzella; Russ Byrum; Catherine Jett; Marisa St Claire; Alvin L Smith; Jason Paragas; Joseph E Blaney; Peter B Jahrling
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.
Journal of virology 2011;85(5):2112-25.
2010: Joseph E Blaney; Anna P Durbin; Brian R Murphy; Stephen S Whitehead
Targeted mutagenesis as a rational approach to dengue virus vaccine development.
Current topics in microbiology and immunology 2010;338():145-58.
2008: Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhagvanji Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian Murphy; Stephen S Whitehead
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
The American journal of tropical medicine and hygiene 2008;79(5):678-84.
2008: Joseph E Blaney; Jim Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian Murphy; Alexander G Pletnev
Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.
Vaccine 2008;26(33):4150-9.
2008: Joseph E Blaney; Neeraj S Sathe; Laura B Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Vaccine 2008;26(6):817-28.
2007: Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian Murphy
Prospects for a dengue virus vaccine.
Nature reviews. Microbiology 2007;5(7):518-28.
2007: Joseph E Blaney; Neeraj S Sathe; Christopher T Hanson; Cai-Yen Firestone; Brian Murphy; Stephen S Whitehead
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Virology journal 2007;4():23.
2006: Anna P Durbin; Julie H McArthur; Jennifer A Marron; Joseph E Blaney; Bhagvanji Thumar; Kimberli Wanionek; Brian Murphy; Stephen S Whitehead
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
Human vaccines 2006;2(6):255-60.
2006: Anna P Durbin; Julie H McArthur; Jennifer A Marron; Joseph E Blaney; Bhagvanji Thumar; Kim Wanionek; Brian Murphy; Stephen S Whitehead
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Human vaccines 2006;2(4):167-73.
2006: Joseph E Blaney; Anna P Durbin; Brian Murphy; Stephen S Whitehead
Development of a live attenuated dengue virus vaccine using reverse genetics.
Viral immunology 2006;19(1):10-32.
2005: Joseph E Blaney; Jennifer M Matro; Brian Murphy; Stephen S Whitehead
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Journal of virology 2005;79(9):5516-28.
2005: Anna P Durbin; Stephen S Whitehead; Julie H McArthur; John R Perreault; Joseph E Blaney; Bhagvanji Thumar; Brian Murphy; Ruth A Karron
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
The Journal of infectious diseases 2005;191(5):710-8.
2004: Joseph E Blaney; Christopher T Hanson; Cai-Yen Firestone; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
The American journal of tropical medicine and hygiene 2004;71(6):811-21.
2004: Joseph E Blaney; Christopher T Hanson; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
BMC infectious diseases 2004;4():39.
2004: Kathryn A Hanley; Luella R Manlucu; Gracielle G Manipon; Christopher T Hanson; Stephen S Whitehead; Brian Murphy; Joseph E Blaney
Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Vaccine 2004;22(25-26):3440-8.
2004: Brian Murphy; Joseph E Blaney; Stephen S Whitehead
Arguments for live flavivirus vaccines.
Lancet 2004;364(9433):499-500.
2003: Joseph E Blaney; Gracielle G Manipon; Cai-Yen Firestone; Daniel H Johnson; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.
Vaccine 2003;21(27-30):4317-27.
2003: Stephen S Whitehead; Kathryn A Hanley; Joseph E Blaney; Lara E Gilmore; William R Elkins; Brian Murphy
Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Vaccine 2003;21(27-30):4307-16.
2003: Kathryn A Hanley; Luella R Manlucu; Lara E Gilmore; Joseph E Blaney; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.
Virology 2003;312(1):222-32.
2003: Joseph E Blaney; Gracielle G Manipon; Brian Murphy; Stephen S Whitehead
Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice.
Archives of virology 2003;148(5):999-1006.
2002: Joseph E Blaney; Daniel H Johnson; Gracielle G Manipon; Cai-Yen Firestone; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.
Virology 2002;300(1):125-39.
2002: Kathryn A Hanley; Jay J Lee; Joseph E Blaney; Brian Murphy; Stephen S Whitehead
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.
Journal of virology 2002;76(2):525-31.
2001: Joseph E Blaney; Daniel H Johnson; Cai-Yen Firestone; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Journal of virology 2001;75(20):9731-40.